

(RIA), radioreceptor assay (RRA), and fluorescent activated cell sorting (FACS). A two-site monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on PRO317 is preferred, but a competitive binding assay may be employed. These assays are described, among other places, in Maddox *et al.* J Exp. Med., 158:1211 (1983).

Please replace the paragraph beginning at page 250, line 1 with the following paragraph:

-- The following materials have been deposited with the American Type Culture Collection, 10801 University Boulevard, Manassas, VA 20110-2209, USA (ATCC):--

In the Claims:

Please amend claims 39 and 44 to read as follows:

39. (Once amended) An antibody that specifically binds to the polypeptide shown in Figure 118 (SEQ ID NO:339).

44. (Once amended) The antibody of claim 39 which specifically binds to the polypeptide shown in Figure 118 (SEQ ID NO: 339), wherein said antibody is a bispecific antibody that also binds to another antigen.

REMARKS

The foregoing amendments in the specification and claims are of formal nature and do not introduce new matter.

Claims 39-44 are pending in this application, and stand rejected on various grounds. The present Amendment and Response is accompanied by the payment of the requisite fee for a two-month extension of time, therefore, the present response is timely filed.

Specification